Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART).

ABSTRACT:

Background

De novo steatosis is the main criteria for non-alcoholic fatty liver disease (NAFLD), which is becoming a clinically relevant comorbidity in HIV-infected patients. This may be due to the HIV virus itself, as well as long-term toxicities deriving from antiretroviral therapy. Therefore, HIV infected patients require prevention and monitoring regarding NAFLD.

Methods

This study investigated the differential role of body mass index (BMI) and combination antiretroviral treatment (cART) drugs on NAFLD progression. This single center prospective longitudinal observational study enrolled HIV monoinfected individuals between August 2013 to December 2018 with yearly visits. Each visit included liver stiffness and steatosis [defined as controlled attenuation parameter (CAP)>

SUBMITTER: Bischoff J 

PROVIDER: S-EPMC8427211 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature